Show simple item record

dc.contributor.authorFrers R.A.K.
dc.contributor.authorCosentino V.
dc.contributor.authorTau J.
dc.contributor.authorKerzberg E.M.
dc.contributor.authorUrdapilleta A.
dc.contributor.authorChiocconi M.
dc.contributor.authorKogan N.
dc.contributor.authorOtero-Losada M.
dc.contributor.authorCapani F.
dc.date.accessioned2020-09-02T22:18:00Z
dc.date.available2020-09-02T22:18:00Z
dc.date.issued2018
dc.identifier10.3389/fimmu.2018.00139
dc.identifier.citation9, FEB, -
dc.identifier.issn16643224
dc.identifier.urihttps://hdl.handle.net/20.500.12728/4527
dc.descriptionStudies on the inflammatory burden in recent-onset psoriatic arthritis (PsA) patients without conventional cardiovascular risk factors (CVRFs) are not available. This preliminary study focuses on cardiovascular risk in cutaneous psoriasis (CPs) and recent-onset PsA patients. Blood biochemistry (glucose, cholesterol, uric acid, lipid profile and apolipoprotein B) was analyzed using standard kits. Proatherogenic inflammation markers, C-reactive protein (CRP) and interleukin-6 (IL-6), and endothelial activators monocyte chemoattractant protein-1 (MCP-1) and soluble intercellular adhesion molecule-1 (sICAM-1), were determined by enzyme-linked immunosorbent assay. Ultrasound images allowed measuring carotid intima-media thickness (cIMT). Our study first shows an increase in cIMT, and in serum levels of sICAM-1 and CRP in recent-onset PsA patients not presenting conventional CVRFs over the non-medicated time-period, from disease diagnosis to the beginning of pharmacological treatment, compared with healthy subjects. The outcome highlights the importance of monitoring serum level of sICAM1, CRP, and cIMT, and the value of primary prevention in psoriatic patients even with no history of cardiovascular events. © 2018 Kolliker Frers, Cosentino, Tau, Kerzberg, Urdapilleta, Chiocconi, Kogan, Otero-Losada and Capani.
dc.language.isoen
dc.publisherFrontiers Media S.A.
dc.subjectAtherogenesis
dc.subjectAtherosclerosis
dc.subjectC-reactive protein
dc.subjectCarotid intima-media thickness
dc.subjectChronic inflammation
dc.subjectIL-6
dc.subjectPsoriatic arthritis
dc.subjectSoluble intercellular adhesion molecule-1
dc.subjectC reactive protein
dc.subjectintercellular adhesion molecule 1
dc.subjectinterleukin 6
dc.subjectmonocyte chemotactic protein 1
dc.subjecttumor necrosis factor
dc.subjectadult
dc.subjectaged
dc.subjectanthropometry
dc.subjectarterial wall thickness
dc.subjectArticle
dc.subjectatherosclerosis
dc.subjectbody mass
dc.subjectcardiovascular risk
dc.subjectcontrolled study
dc.subjectdisease activity score
dc.subjectechography
dc.subjectenzyme linked immunosorbent assay
dc.subjectfemale
dc.subjecthuman
dc.subjecthyperinsulinemia
dc.subjecthypertension
dc.subjectinflammation
dc.subjectmale
dc.subjectmetabolic syndrome X
dc.subjectPsoriasis Area and Severity Index
dc.subjectpsoriatic arthritis
dc.titleImmune-mediated inflammation promotes subclinical atherosclerosis in recent-onset psoriatic arthritis patients without conventional cardiovascular risk factors
dc.typeArticle


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record